5 Most Promising Penny Stocks According to Analysts
Germany-based Affimed N.V. (NASDAQ:AFMD) is working on cancer immunotherapies. Affimed N.V.
Checkpoint Therapeutics Inc. (CKPT)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Armistice Capital Steven Boyd | 3,886,000 | $8,704,640 | +56% | 0.13% |
| 2. | 1,761 | $394,464 | -35% | 0.21% | |
| 3. | 163,600 | $366,464 | -17% | 0% | |
| 4. | Renaissance Technologies Jim Simons | 88,790 | $198,890 | +16% | 0% |
| 5. | D E Shaw D. E. Shaw | 88,422 | $198,065 | +93% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.27 | 100,000 | Director | 237,890 | 2019-11-20 | Filing | |
| $2.35 | 49,666 | Director | 126,448 | 2018-11-09 | Filing | |
| $2.24 | 48,234 | Director | 76,782 | 2018-11-08 | Filing | |
| $2.12 | 2,100 | Director | 28,548 | 2018-11-07 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $3.38 | 220,230 | Officer, Director | 3,194,583 | 2024-12-19 | Filing | |
| $3.87 | 602,167 | Officer, Director | 3,414,813 | 2024-12-18 | Filing | |
| $4.01 | 268,432 | Officer | 1,032,754 | 2024-12-18 | Filing | |
| $2.05 | 24,610 | Officer, Director | 1,977,170 | 2024-06-26 | Filing | |
| $2.06 | 13,038 | Officer | 672,186 | 2024-06-26 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 548,308 | $1,255,625 | 0% | |
| 2. | 173,844 | $398,206 | 0% | |
| 3. | 166,516 | $381,321 | 0% | |
| 4. | 163,283 | $373,902 | 0% | |
| 5. | 95,062 | $217,692 | 0% |
News See All
5 Best Rated Penny Stocks to Buy According to Analysts
Germany-based Affimed is trading at $0.64 as of July 13, while its analyst price target is $6. This stock price target shows an upside potential of a whopping 837% from the current levels.
Is Checkpoint Therapeutics, Inc. (CKPT) A Good Stock To Buy?
Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first.
Hedge Funds Are Warming Up To Checkpoint Therapeutics, Inc. (CKPT)
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings.
Hedge Fund and Insider Trading News: Jonathan Litt, Mike Novogratz, The Medicines Company (MDCO), Checkpoint Therapeutics Inc (CKPT), Koppers Holdings Inc. (KOP), and More
Nov 28 (Reuters) - Activist investor Jonathan Litt on Wednesday renewed call for the sale of the Saks Fifth Avenue brand, while asking owner Hudson’s Bay Co to make new board appointments, saying the...
Hedge Fund and Insider Trading News: Carl Icahn, Anthony Scaramucci, Crispin Odey, Toscafund Asset Management, Roadrunner Transportation Systems Inc (RRTS), Checkpoint Therapeutics Inc (CKPT), and More
Dell Technologies Inc. has one class of publicly listed stock outstanding, a tracking stock (referred to as DVMT) that it issued as part of its acquisition of EMC Corp.
Billionaire Hedge Funds
